GlassScriptPhysician profile
Cassandra L Williamson
NPI 1457565392
$6,827.61
in general payments reported to CMS, 2019-2025
31 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $924 · 2022: $1,234 · 2023: $1,082 · 2024: $1,608 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,570 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,570.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,360.09 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,202.02 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $740.59 | 2022-2025 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $410.46 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.86 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $319.42 | 2021-2025 | Epclusa |
| Qol Medical, LLC | $241.47 | 2021-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $235.03 | 2021-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $115.38 | 2025 | Iqirvo |
| Ardelyx, INC. | $81.75 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $67.28 | 2025 | Dupixent |
| Pfizer INC. | $66.59 | 2021 | |
| Nestle Healthcare Nutrition INC. | $66.43 | 2021-2022 | |
| Braintree Laboratories, INC. | $63.55 | 2021-2025 | Suflave, Sutab |
| Novo Nordisk INC | $59.48 | 2025 | Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $56.57 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Aimmune Therapeutics, INC. | $43.53 | 2025 | Vowst, Zenpep |
| Madrigal Pharmaceuticals | $41.67 | 2025 | Rezdiffra |
| Celgene Corporation | $34.28 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $32.44 | 2022-2023 | Linzess |
| Daiichi Sankyo INC. | $31.24 | 2021 | |
| Azurity Pharmaceuticals, INC. | $25.99 | 2025 | Suflave |
| Celltrion USA INC. | $24.45 | 2025 | Vegzelma |
| Lilly USA, LLC | $23.00 | 2024 | Omvoh |
| Alexion Pharmaceuticals, INC. | $16.61 | 2023 | Ultomiris |
| Fresenius Kabi USA, LLC | $16.48 | 2023 | |
| Evoke Pharma, INC. | $14.75 | 2023 | Gimoti |
| Organon LLC | $14.58 | 2023 | Hadlima, Renflexis |
| Alnylam Pharmaceuticals INC. | $14.39 | 2022 | |
| Merck Sharp & Dohme LLC | $12.32 | 2021 | |
| Phathom Pharmaceuticals, INC. | $5.91 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.